Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with type 2 diabetes: A double tracer OGTT study

Clinical Endocrinology

Volumn 73, Issue 3, 2010, Pages 339-345

  Glass, Leonard C ^a   Cusi, Kenneth ^a   Berria, Rachele ^a   Petz, Roberta ^b   Cersosimo, Eugenio ^a   Defronzo, Ralph A ^a   Gastaldelli, Amalia ^a,b  

^a University of Texas Health Science Center at San Antonio   (United States)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 GLUCOSE C 14; 3 GLUCOSE H 3; CARBON 14; GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; RADIOPHARMACEUTICAL AGENT; SULFONYLUREA; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HISPANIC; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TREATMENT DURATION;

BLOOD GLUCOSE; CARBON RADIOISOTOPES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; METABOLIC CLEARANCE RATE; MEXICAN AMERICANS; MIDDLE AGED; TEXAS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TRITIUM;

EID: 77955760734     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03811.x     Document Type: Article

References (23)

1. DeFronzo, R.A. (1988) Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes, 37, 667 687.
2. DeFronzo, R.A. (1997) Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Reviews 5, 177 269.
3. Gulli, G., Ferrannini, E., Stern, M. et al. (1992) The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 41, 1575 1586.
4. Reaven, G.M. Olefsky, J.M. (1977) Relationship between heterogeneity of insulin responses and insulin resistance in normal subjects and patients with chemical diabetes. Diabetologia 13, 201 206.
5. Maggs, D.G., Buchanan, T.A., Burant, C.F. et al. (1998) Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 128, 176 185.
6. Kim, Y.B., Ciaraldi, T.P., Kong, A. et al. (2002) Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 51, 443 448.
7. Mayerson, A.B., Hundal, R.S., Dufour, S. et al. (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51, 797 802.
8. Miyazaki, Y., Mahankali, A., Matsuda, M. et al. (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24, 710 719.
9. Miyazaki, Y., Glass, L., Triplitt, C. et al. (2001) Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 44, 2210 2219.
10. Miyazaki, Y., Mahankali, A., Wajcberg, E. et al. (2004) Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 89, 4312 4319.
11. Miyazaki, Y., Matsuda, M. DeFronzo, R.A. (2002) Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25, 517 523. (Pubitemid 41103346)
12. Ferrannini, E., Bjorkman, O., Reichard Jr., G.A. et al. (1985) The disposal of an oral glucose load in healthy subjects. A quantitative study. Diabetes 34, 580 588.
13. Ferrannini, E., Simonson, D.C., Katz, L.D. et al. (1988) The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism 37, 79 85.
14. Kuyumjian, J. Kalant, N. (1986) Absorption of an oral glucose load in the dog. Hormone and Metabolic Research 18, 587 589.
15. DeFronzo, R.A. (1999) Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine 131, 281 303.
16. Smith, S.A., Porter, L.E., Biswas, N. et al. (2004) Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 89, 6048 6053.
17. Gastaldelli, A., Ferrannini, E., Miyazaki, Y. et al. (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47, 31 39.
18. Gastaldelli, A., Casolaro, A., Pettiti, M. et al. (2007) Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. Clinical Pharmacology and Therapeutics 81, 205 212.
19. Mari, A. (1992) Estimation of the rate of appearance in the non-steady state with a two-compartment model. American Journal of Physiology 263, E400 E415.
20. Ludvik, B., Nolan, J.J., Roberts, A. et al. (1995) A noninvasive method to measure splanchnic glucose uptake after oral glucose administration. Journal of Clinical Investigation 95, 2232 2238.
21. Matsuda, M. DeFronzo, R.A. (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462 1470.
22. Groop, L.C., Bonadonna, R.C., DelPrato, S. et al. (1989) Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. Journal of Clinical Investigation 84, 205 213.
23. Gastaldelli, A., Miyazaki, Y., Mahankali, A. et al. (2006) The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 29, 2275 2281.